JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Home・Akciju saraksts・Pulmatrix Inc

Pulmatrix Inc

Slēgts

2.53 -0.39

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.5

Max

2.62

Galvenie mērījumi
By Trading Economics
Ienākumi	672K -877K
EPS	-0.24
Peļņas marža	-60,266.667
Darbinieki	2
EBITDA	671K -877K

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-8.4M 9.5M
Iepriekšējā atvēršanas cena	2.92
Iepriekšējā slēgšanas cena	2.53

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. febr. 00:00 UTC

Karstas akcijas

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

2026. g. 4. febr. 22:55 UTC

Peļņas

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

2026. g. 4. febr. 21:44 UTC

Peļņas

Arm Holdings 3Q Profit Falls Despite Revenue Growth

2026. g. 4. febr. 21:39 UTC

Peļņas

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

2026. g. 5. febr. 00:00 UTC

Peļņas

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

2026. g. 5. febr. 00:00 UTC

Peļņas

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

2026. g. 4. febr. 23:46 UTC

Tirgus saruna

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

2026. g. 4. febr. 23:45 UTC

Peļņas

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

2026. g. 4. febr. 23:32 UTC

Tirgus saruna

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

2026. g. 4. febr. 22:59 UTC

Iegādes, apvienošanās, pārņemšana

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

2026. g. 4. febr. 22:30 UTC

Peļņas

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

2026. g. 4. febr. 22:30 UTC

Peļņas

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

2026. g. 4. febr. 22:21 UTC

Peļņas

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026. g. 4. febr. 22:17 UTC

Tirgus saruna

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

2026. g. 4. febr. 22:15 UTC

Tirgus saruna

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

2026. g. 4. febr. 22:00 UTC

Tirgus saruna

ESG Roundup: Market Talk

2026. g. 4. febr. 21:53 UTC

Peļņas

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

2026. g. 4. febr. 21:51 UTC

Peļņas

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026. g. 4. febr. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 4. febr. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 4. febr. 21:50 UTC

Tirgus saruna

Peļņas

Auto & Transport Roundup: Market Talk

2026. g. 4. febr. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 4. febr. 21:45 UTC

Peļņas

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

2026. g. 4. febr. 21:44 UTC

Peļņas

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

2026. g. 4. febr. 21:43 UTC

Peļņas

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

2026. g. 4. febr. 21:41 UTC

Peļņas

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

2026. g. 4. febr. 21:36 UTC

Tirgus saruna

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

2026. g. 4. febr. 21:30 UTC

Peļņas

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026. g. 4. febr. 21:30 UTC

Peļņas

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026. g. 4. febr. 21:30 UTC

Peļņas

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pulmatrix Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.